IXICO plc (LSE:IXI), a specialist in AI-powered neuroscience imaging and biomarker analytics, has raised its revenue expectations for the financial year ending 30 September 2026 following strong commercial performance. The company provides imaging contract research services to pharmaceutical companies, biotechnology firms, disease consortia and non-profit organisations developing treatments for neurological conditions, using its proprietary IXI platform to support global clinical trials in diseases including Alzheimer’s, Huntington’s and Parkinson’s.
The company now expects annual revenue of at least £8.0 million, exceeding previous forecasts and representing approximately 22% growth compared with FY2025. IXICO said the improved outlook reflects strong trading, new contract awards, project extensions and a broader mix of revenue streams. Management believes the performance demonstrates the success of the strategic plan launched in 2024, strengthening the company’s position in neuroscience imaging and reinforcing its role as a partner to drug developers seeking reliable imaging data and biomarker analysis for clinical research.
The investment outlook continues to be weighed down by ongoing losses and negative operating cash flow. However, these challenges are partly offset by improving commercial momentum, stronger operating leverage, high levels of contracted revenue visibility and a strengthened cash position following the company’s recent capital raise. Technical indicators remain positive, although the shares appear overbought, while valuation metrics continue to be affected by the absence of profitability and dividend payments.
More about IXICO plc
IXICO plc is a neuroscience imaging and biomarker analytics company that operates as an end-to-end Imaging Contract Research Organisation (iCRO) for global pharmaceutical and biotechnology clients. Through its proprietary AI-driven IXI platform, the company supports clinical trials targeting neurological diseases including Alzheimer’s, Huntington’s and Parkinson’s, helping improve the accuracy of biomarker measurement throughout the drug development process.
With more than two decades of experience in neurological disease research, IXICO has analysed hundreds of thousands of brain scans and established an extensive international network of specialist imaging centres. Its technology platform processes complex imaging data from multinational clinical studies, combining advanced artificial intelligence with scientific expertise to deliver reliable, reproducible insights for researchers and drug developers.
Leave a Reply